Cadence Minerals PLC - Exercise of Warrants
RNS Number : 4314L
Cadence Minerals PLC
12 January 2021

Cadence Minerals Plc


("Cadence Minerals", "Cadence" or "the Company")


Exercise of Warrants


Cadence Minerals (AIM/NEX: KDNC; OTC: KDNCY) announce that, it has received warrant exercise notices to subscribe for 300,000 new ordinary shares in the Company at an exercise price of 8.5 pence per share (the "Warrant Shares") Subscription monies of £25,500 have been received by the Company in respect of the exercise of these warrants.


Application will be made for the Warrant Shares to be admitted to trading on AIM of plc and to and the AQSE Growth Market operated by Aquis Exchange Plc ("Admission").


Admission is expected to occur on or around 19 January 2021. Upon Admission, the Company will have 148,349,098 Ordinary Shares in issue. There are no shares held in treasury. The total voting rights in the Company is therefore 148,349,098 and Shareholders may use this figure as the denominator by which they are required to notify their interest in, or change to their interest in, the Company under the Disclosure Guidance and Transparency Rules.


- Ends -


This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.


For further information:


Cadence Minerals plc

+44 (0) 7879 584153

Andrew Suckling

Kiran Morzaria

WH Ireland Limited (NOMAD & Broker)

+44 (0) 207 220 1666

James Joyce

James Sinclair-Ford

Novum Securities Limited (Joint Broker)

+44 (0) 207 399 9400

Jon Belliss


This information is provided by RNS, the news service of the . RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the use the personal data you provide us, please see our Privacy Policy.